Subscribe

Past Issues

Translate ▼

THE CANADIAN CHILDREN INFLAMMATORY BOWEL DISEASE NETWORK:

A PARTNERSHIP WITH THE CH.I.L.D FOUNDATION







Jump to: Education | Publications, Awards & Grants

CIDSCANN ANNUAL MEETING

After 2.5 years of virtual meetings, we are finally able to meet face to face!

This will be aligned with the Meeting of the Minds (Mentoring in IBD and CCC Future Directions in IBD), so that anyone intending to come to Toronto could make plans to arrive in time for the CIDsCaNN meeting.

Virtual attendance is also possible for those not coming to Toronto.

WATCH YOUR EMAIL FOR DETAILS & REGISTRATION!

NOV 3 STARTING IN THE MORNING
- UNTIL 4 P.M.


SEE YOU THERE!

Past Issues

Translate >







Phase 2 CIDsCaNN: AMBITION-CD

Assessment of Mucosal Biochemical and clinical response to Interleukin-12/23 or TNF InhibitOrs in biologic-Naïve Crohn's Disease

Inclusion criteria: Children age 2-17y with Crohn's disease starting first biologic as antiTNF or UST for luminal Crohn's disease

Participating sites: All

Target: 200 antiTNF, 100 UST

Contact: Michelle

<u>michelle.ouzounis@sickkids.ca</u> Contact: Hayley <u>hayley.mackay@sickkids.ca</u>

Phase 2 enrolment into a prospective cohort of children and adolescents anticipated to initiate biologic therapy for luminal inflammatory Crohn's disease has begun.

As discussed at the investigator meetings, when patients are willing to provide biopsies for research, we **encourage enrolment prior to diagnostic (or**

If such an enrolled patient turns out to have ulcerative colitis or IBD-U rather than Crohn's disease, they will not be eligible for the AMBITION- CD analysis, and will not continue to be followed in the cohort. For these non-eligible patients, remuneration will be provided only for data and biospecimens collected at the time of enrolment.

We hope that this does not happen often, but we will be able to track occurrences by comparing enrolment numbers and ZOHO registrations when first dose of anti-TNF or ustekinumab is given to AMBITION-CD cohort patients.

Subscribe Past Issues Translate ▼

will be confirmed and that biologic therapy for luminal inflammatory Crohn's disease will be initiated early.

Biospecimen Type	Baseline (Date 0 or Anchor Date)
Biopsies	15 (44%)
DNA	21 (62%)
RNA	25 (74%)
Serum	26 (76%)
Stool	17 (50%)

Site	Enrolled in AMBITION-CD	Biologic		
- 100		Ustekinumab	Anti TNF	
Toronto	20	6	14	
London	4	1	3	
Edmonton	8	4	4	
Halifax	2	0	2	
St Johns	1	0	1	
Winnipeg	5	1	4	
Total	40	12	28	

Ongoing Follow-up of Inception Cohort Study

• Inclusion criteria: Children age 2-17y with IBD

• Participating sites: All

• Contact: Michelle <u>michelle.ouzounis@sickkids.ca</u>

Dual biologics (via Main Prevalent Cohort Study)

• Inclusion criteria: Children age 2-17y with IBD on 2 concurrent biologics

• Participating sites: All

• Enrolled: 13

• Contact: Wael welmatary@exchange.hsc.mb.ca

Subscribe

Past Issues

Translate **▼**

 Inclusion criteria: Children age 2-17y with luminal IBD starting first anti-TNF without prior surgery nor significant stenotic/penetrating disease requiring surgery in shortterm

Target: 75

Enrolled 59

Participating sites: Toronto, Ottawa, Halifax

• Contact: Amanda Amanda.ricciuto@sickkids.ca

• Contact: Shantel Shantel.mangroo@sickkids.ca

Implementing a Multimodal Intervention to Improve the Transition of Patients with Inflammatory Bowel Disease from Pediatric to Adult Care

 Inclusion criteria: Aged 16-17.5 y with IBD, ability to provide informed consent, ability to speak/read English at a Grade 8 level, intention to reside in Canada after transfer to adult care, access to smartphone/computer (can be purchased for the participant if this is a barrier to participation)

Target: 115Enrolled: 28

Participating sites: Toronto, Ottawa, McMaster, BCCH

• Contact: Eric eric.benchimol@sickkids.ca

Education Update

Upcoming session:

NOVEMBER 1, 2022 3:00pm- 4:30pm EST Thromboprophylaxis in Pediatric Inflammatory Bowel Disease

Recent session:

June 28, 2022: The role of bowel ultrasound in pediatric IBD

Missed it? No problem! Listen to the recording at cidscann.ca/education

Translate >

Subscribe Past Issues

We encourage you to share the Education Session calendar invites with your multidisciplinary teams. Please find the dates for future sessions, and past recordings at cidscann.ca/education






Thank you to all the members who represented CIDsCaNN at the 6th International PIBD Congress in Edinburgh, Scotland!



Translate ▼

Subscribe Past Issues





Subscribe Past Issues Translate ▼



Thank you for your engagement and contribution to CIDSCANN!

Website: www.cidscann.ca | Email: info@cidscann.ca



Copyright © 2022 Canadian Children Inflammatory Bowel Disease Network, All rights reserved.

Our mailing address is:

555 University Avenue, Toronto ON Canada M5G 1X8

tel: 416-813-1500

email: info@cidscann.ca

Want to change how you receive these emails? You can update your preferences or unsubscribe from this list.

Subscribe	Past Issues		Translate ▼	
-----------	-------------	--	-------------	--

This email was sent to << Email Address>>

<u>why did I get this?</u> <u>unsubscribe from this list</u> <u>update subscription preferences</u> CIDsCaNN · 555 University Ave · Toronto, ON M5G 1X8 · Canada

